

AMENDMENT TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application:

- 1-25: (Canceled)
- 26. (Previously Presented) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, wherein the pharmaceutical composition is administered rectally.
- 27. (Currently amended) The method according to claim 26, wherein the pharmaceutical composition ~~comprises~~ consists essentially of recombinant streptokinase and a pharmacologically acceptable diluent carrier or excipient.
- 28. (Previously Presented) The method according to claim 26, wherein the recombinant streptokinase has a concentration of 50,000 to 1,500,000 IU per gram of the pharmaceutical composition.
- 29. (Canceled)
- 30. (Canceled)
- 31. (Canceled)
- 32. (Cancelled)

33. (Previously Presented) The method according to claim 26, wherein the pharmaceutical composition is a suppository.
34. (New) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, and ethylenediaminetetraacetic acid (EDTA) and sodium diclofenac, wherein the pharmaceutical composition is administered rectally.
35. (New) A method for treating hemorrhoid disease in a human in need thereof, comprising administering to said human an effective amount of a pharmaceutical composition, said composition consisting essentially of a thrombolytic protein selected from the group consisting of tissue-type plasminogen activator (t-PA), urokinase (u-PA), streptokinase (SK), or a combination thereof, and ethylenediaminetetraacetic acid (EDTA) and sodium salicylate, wherein the pharmaceutical composition is administered rectally.